Biogen stock surges despite skepticism over Alzheimer’s drug plan

In an analyst note following the news, R.W. Baird’s Brian Skorney wrote that it is “highly unlikely” that the drug will ultimately be approved. Nevertheless, the Cambridge company’s stock rose 36 percent as of 10 a.m., adding $17 billion to the company’s market cap.